Company news

Kamada Ltd. (NASDAQ:KMDA) news

Kamada Ltd. news releases on 6ix. Latest, Oct 6, 2026: Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Kamada Ltd. (NASDAQ:KMDA) news

Press releases & updates

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting

Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory

Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year

Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio

Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

Kamada Reports Strongest Quarter For The Year In Q3, With Over 30% Profitability Increase Year-Over-Year

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

Kamada to Present at the Stifel 2025 Healthcare Conference

Kamada to Participate in Upcoming September Investor Conferences

Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance

Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East

Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth

Kamada Declares Special Cash Dividend of $0.20 Per Share

Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025

Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America

Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025

Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance

Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024

Kamada to Present at the Stifel 2024 Healthcare Conference

Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston

Kamada Reports Strong Second Quarter and First Half 2024 Financial Results with Year-Over-Year 6-Month Top-Line Growth of 18% and a 68% Increase in Profitability

Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024

Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance

Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

Kamada Issues 2024 CEO Letter to Shareholders